This page is kept for reference and is not offered to search engines.
Indication
Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
In other countries
The same active substances on other registers, the same brand first.
- SIXMO 74,2 mg IMPLANTESpain · 80 mg · implante · L. Molteni & C. Dei Fratelli Alitti Societa Di Esercizio S.P.A.Same brand
- buprenorfinaBrazil · Adium S.A.Same form
- LusandaBrazil · Adium S.A.Same form
- RestivaBrazil · Mundipharma Brasil Produtos Médicos e Farmacêuticos LtdaSame form
- BelbucaCanada · 750 MCG · Film (Soluble) · Purdue Pharma